Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is one of Japan's largest pharmaceutical corporations. Its headquarters are in Chuo-ku, Osaka, Japan, and it has large plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka, as well as a central research facility in Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's origins may be traced back to 1717, when Ichibei Ono established his pharmaceutical dealer business in Osaka. His company grew and changed names several times before becoming Ono Pharmaceutical Industrial Co., Ltd. in 1948.

Ono Pharmaceutical has three manufacturing facilities: the Joto Product Development Center, the Yamaguchi Plant, and the Fujiyama Plant. It sells products across the Americas, Europe, and Asia. Ono Pharmaceutical is based in Osaka, Japan. Ono has been listed on the Tokyo Stock Exchange since 1963. Its consolidated earnings for the half year ended March 2018 were 16 billion Japanese yen. Nivolumab, a cancer treatment based on the study of Prof.Dr. Tasuku Honjo of Kyoto University, who was awarded the Nobel Prize later that year, is sold by both Ono Pharmaceutical and Bristol-Myers Squibb.

Founded: 1717

Headquarters: Osaka, Japan

Official website: https://www.ono-pharma.com/en